FY2025 EPS Estimates for Zura Bio Boosted by HC Wainwright

Key Points

• HC Wainwright has raised its FY2025 EPS estimates for Zura Bio to ($0.74) from ($0.76), maintaining a "Neutral" rating with a price target of $2.00.
• Zura Bio reported a quarterly EPS of ($0.17), beating the consensus estimate of ($0.19), indicating a positive outlook from recent performance.
• Institutional investors have increased their holdings in Zura Bio, with 61.14% of the company's stock now owned by institutional investors and hedge funds.

Zura Bio Limited (NASDAQ:ZURA - Free Report) - HC Wainwright raised their FY2025 earnings per share (EPS) estimates for Zura Bio in a report issued on Tuesday, August 19th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.74) per share for the year, up from their previous estimate of ($0.76). HC Wainwright currently has a "Neutral" rating and a $2.00 price target on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.02.

Several other research analysts have also recently commented on ZURA. Chardan Capital reiterated a "buy" rating and issued a $10.00 price target on shares of Zura Bio in a research note on Friday, August 15th. Oppenheimer cut their price objective on Zura Bio from $17.00 to $16.00 and set an "outperform" rating on the stock in a research note on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Zura Bio presently has a consensus rating of "Buy" and a consensus price target of $14.00.

Zura Bio Stock Performance

NASDAQ:ZURA opened at $1.75 on Thursday. Zura Bio has a one year low of $0.97 and a one year high of $5.07. The business's 50-day simple moving average is $1.40 and its 200 day simple moving average is $1.32. The stock has a market cap of $119.67 million, a price-to-earnings ratio of -2.50 and a beta of -0.06.

Institutional Trading of Zura Bio

Institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN grew its holdings in shares of Zura Bio by 68.6% during the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after purchasing an additional 9,379 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Zura Bio by 31.9% during the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company's stock valued at $103,000 after purchasing an additional 9,966 shares during the last quarter. Two Sigma Advisers LP bought a new position in shares of Zura Bio during the fourth quarter valued at approximately $32,000. ProShare Advisors LLC bought a new position in shares of Zura Bio during the fourth quarter valued at approximately $35,000. Finally, Barclays PLC grew its holdings in shares of Zura Bio by 22.6% during the fourth quarter. Barclays PLC now owns 78,523 shares of the company's stock valued at $197,000 after purchasing an additional 14,462 shares during the last quarter. Institutional investors and hedge funds own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.